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State-space size considerations for
disease-progression models
Eva D. Regniera*† and Steven M. Shechterb
Markov models of disease progression are widely used to model transitions in patients’ health state over time.
Usually, patients’ health status may be classified according to a set of ordered health states. Modelers lump
together similar health states into a finite and usually small, number of health states that form the basis of
a Markov chain disease-progression model. This increases the number of observations used to estimate each
parameter in the transition probability matrix. However, lumping together observably distinct health states also
obscures distinctions among them and may reduce the predictive power of the model. Moreover, as we demon-
strate, precision in estimating the model parameters does not necessarily improve as the number of states in the
model declines. This paper explores the tradeoff between lumping error introduced by grouping distinct health
states and sampling error that arises when there are insufficient patient data to precisely estimate the transition
probability matrix. Copyright © 2013 John Wiley & Sons, Ltd.
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1. Introduction
Markov models are applied extensively in healthcare modeling to represent the probabilistic transitions
of patients’ health over their lifetimes [1,2]. They may be used for prediction (e.g., ‘what is this patient’s
expected lifetime?’) or to support decision making (e.g., ‘for which health states should patients ini-
tiate therapy, and for which health states should they wait?’). Usually, patients’ health status may be
readily classified according to an ordered set of health states. For example, HIV patients’ health sta-
tus is often classified according to their CD4 count. Each level of CD4 count may be thought of as
a distinct state, and the states are naturally ordered (i.e., lower CD4 counts are associated with worse
prognosis). Modelers commonly partitioned the scale into a small number of states for modeling as a
Markov chain. The choice of state definition often varies across models even for the same disease pro-
cess; for example, one HIV modeling paper partitions CD4 count (the number of CD4 white blood cells
per cubic millimeter of blood) into reduced-model states of [0,50], [51,100], [101,200], [201,300] [3],
another uses [0,49], [50,199], [200,349], > 350 [4], and yet another uses [0,199], [200,499], [500,699],
[700,899], > 900 [5]. These and several other Markov models of disease progression treat the state
definition as exogenous and use the patient data to estimate transition probability matrices (TPMs)
over the already-defined states. The state-space sizes of three to five in the HIV models cited earlier
are typical of disease-progression models in the medical decision-making (MDM) literature (see other
disease-progression models described and cited in [6]).
There are various reasons for defining model states that lump together many observably distinct health
states. From a clinical perspective, it is simpler to describe, understand, and recall treatment guidelines
with a small number of categories with simple breakpoints. For example, guidelines on the appropriate
time to initiate HIV therapy are typically described in terms of what to do if a patient’s CD4 count is
less than 200, between 200 and 350, 350 and 500, or more than 500 [7]. A large state space may also
create computational challenges for optimization of treatment decisions. Although computing power
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is increasingly available, if there are a large number of treatment options, the curse of dimensionality
can make the optimization problem computationally intractable. More important, when TPMs must be
estimated from observational data, lumping is a way to deal with data sparsity. Returning to the HIV
example, the upper bound on the normal range of CD4 count for healthy patients is 1500, so the com-
plete state space has at least 1500 distinct states, that is, CD4 count D 1; 2; : : : ; 1500. Depending on
the amount of patient data available, generating reliable estimates for the 1500  1501 TPM (including
death) may pose a problem.
This paper investigates the choice of the size of the state space for a Markov chain disease-progression
model when there are limited data with which to estimate the TPM. The decision requires a trade-
off between accuracy and precision: lumping increases observation counts in each state, which may
reduce the sampling error about the estimates of transition probabilities for the reduced-state model
(greater precision). However, the precision comes at the cost of obscuring the actual differences in tran-
sition probabilities across observably distinct health states that are lumped together (lower accuracy).
Even if the disease actually progresses according to a Markov chain, for reasonable models of disease
progression, lumping also leads to a loss of the Markovian property and will increase errors in predic-
tions especially over periods of more than one time step, including predictions of a patient’s remaining
lifetime. Moreover, our results indicate that the precision gains due to lumping may be smaller than
modelers assume.
The implication is that instead of a predetermined partition of states for a disease process, the size of
the reduced model should depend on the amount of data available for estimating the TPM. The effects
of lumping and sampling error are also dependent on the structure of the underlying TPM. Therefore,
the choice of model size should also be informed by the available data and other available information
about the behavior of the disease reflecting the structure of the underlying complete TPM.
The tradeoff between accuracy and precision (equivalently, between lumping and sampling error)
is difficult to quantify. In this paper, we propose metrics for evaluating and comparing the accuracy,
precision, and predictive performance for a given state-space definition and compare various choices
using computational experiments. A key factor in this investigation is the quantity of data observed;
if there were an infinite number of patient transitions observed, estimating the TPM would require no
lumping (for discrete health states).
In Section 2, we discuss relevant literature from the fields of MDM, Markov decision processes
(MDPs), and statistics with regard to both estimating transition probabilities for a Markov chain and
examining the effects of lumping. In Section 3, we discuss the assumptions and properties of our model
and propose metrics for evaluating lumping and sampling error. Section 4 presents analytical and com-
putational results. In Section 5, we use a real HIV dataset to show the effect of the size of the state space
on a model of HIV progression and suggest and illustrate an approach to selecting an appropriate model
size based on a dataset. Section 6 offers insights gleaned from this work and directions for future work.
2. Background
The literature contains early discussions of transition probability estimation and statistical inference for
Markov chains (e.g., [8] and [9]). A number of papers in the MDM and healthcare literature examine how
to handle various challenges that arise when estimating TPMs in Markov models of disease, including
irregular observation times, incomplete data, and censored observations [10–18].
There is very little prior work on the effects of alternative model designs and, in particular, on the
choice to lump observable health states to serve as the states of a Markov chain. Bentley et al. [19]
examined bias effects when discretizing continuous health variables and cited the two motivations noted
earlier for even considering state aggregation in the first place: model complexity and limited data.
They used computational experiments to compare a Monte Carlo simulation, which reflects individuals’
varying risk factors within a category, with a Markov cohort simulation, which uses an average category
risk factor to represent the risk level of all patients in that category. In their underlying disease model,
patients can transition from many (continuous or discrete) states of wellness to a single diseased state,
with transition probabilities a function of their health state. They measured bias in the estimated effect
on life expectancy of an intervention to extend life expectancy and found that discretization does create
bias, but that it is generally low and decreasing in the number of discrete states modeled. The relation-
ship between aggregation choice and the quantity of data available was not considered. Faissol et al. [6]
examined bias created by aggregating data to compute transition probabilities and the failure to estimate
state-specific and/or age-specific probabilities of transitioning to worse health states. They found that
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2013, 32 3862–3880
3863
E. D. REGNIER AND S. M. SHECHTER
bias can be significant but did not discuss the impact of data availability. Both those results motivate a
greater attention to the state-definition decision and the choice of the degree of lumping, that is, the size
of the reduced state space.
The operations research literature discusses state aggregation and disaggregation in the context of
computational tractability for optimization problems, including MDPs; for a review of this literature, see
[20]. The artificial intelligence literature has addressed the aggregation problem (which they call state
abstraction) in more detail in developing learning algorithms that simplify the state space in the context
of the MDP, including actions and rewards (e.g., [21]). This literature assumes that the original state
space is prohibitively large for solving the MDP to optimality, and the motivation is to find a policy that
approximates optimality.
In the MDM literature, the definition of the disease-progression model is typically, and perhaps uni-
versally, handled separately from the treatment decisions. The Markov property is often simply assumed
to hold for reduced models that result from state aggregation, much as researchers often proceed as if
a continuous-time Markov chain will retain the Markov property when treated as a discrete-time chain.
However, it is well known that even if the complete-state model transitions according to a Markov chain,
a reduced-state model representation may no longer satisfy the Markov property [22]. In this work, we
investigate the impact of reducing the model size given the assumption that the disease actually does
progress according to a Markov chain.
In any reasonable disease-progression model in which transitions over the original states are
Markovian, the transitions over the reduced-model states will not be Markovian. Thomas and Barr [23],
citing [22], offer a necessary and sufficient condition for a Markov chain to be ‘lumpable’ with respect
to a given reduction, meaning the Markov property is retained in the reduced model. The condition is
that for any pair of reduced-model states, k and l (including k D l), the total probability of transitioning
in one step from any original state i to the set of original states in l is identical for all i in k.
In general, reasonable disease-progression models will violate this condition for any model reduction.
The decreasing failure rate (DFR) property (described in Section 3.5) is typical of disease progression
and means that patients in worse health will have a greater probability of transitioning to poor health
states, compared with patients in better health. If the DFR property holds strictly, it will certainly cause
a violation of the lumpability condition regardless of the model reduction chosen. A violation would
also occur for reduced models that preserve death as its own state but lump together any two observable
health states that have different single-step death probabilities.
We focus on the modeling decision—state definition—which is required before proceeding to con-
sider a treatment decision problem. That is, before using a TPM and other model parameters to solve
for optimal treatment policies or estimate patient outcomes, a modeler must first construct one or more
disease-progression model(s) from patient data. Therefore, we consider model reduction for the purposes
of TPM estimation and evaluate the performance of different choices of model size. Although the
previous literature discusses several important modeling considerations, we are unaware of any papers
that consider the combination of transition probability estimation and model reduction.
3. Modeling framework
Our purpose is to investigate error caused by lumping distinct health states in disease-progression
modeling and to compare that error with error due to imprecise parameter estimates. Although many
diseases are not inherently Markovian, we examine what happens when the Markovian assumption does
hold; that is, the fundamental modeling error is not the Markovian assumption but rather reducing the
state space. We therefore assume that the probabilistic evolution of patient health prior to initiating ther-
apy (sometimes referred to as the natural history of a disease) follows a first-order stationary Markov
chain, and the modeler’s challenge is to define the state space and estimate the unknown transition prob-
abilities based on patient data, motivating the consideration of model reduction for estimation purposes.
We construct hypothetical TPMs to explore the behavior of samples and sample-derived models, which
we can compare with the behavior of the actual (hypothetical) disease. This allows us to directly investi-
gate the relationship between quantity of data and the model-reduction choice when estimating transition
probabilities in Markov model, avoiding complications such as whether the Markovian property holds
for a particular disease or dataset, how to handle observations taken at irregular intervals, and how to deal
with censored natural history transitions that occur when patients initiate therapy. This analysis provides
insight into appropriate aggregation choice when the modeler has only a limited amount of patient data,
which we illustrate with real HIV patient data in Section 5.
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3.1. The disease-progression model
We assume that a patient’s state of health can be described by i 2 f0; 1; 2; : : : ; J g, with state 0
representing death and increasing i representing improving levels of health. We suppose the patient’s
health state transitions according to a stationary discrete-time Markov chain (DTMC) characterized by
TPM P (with pij representing the one-step transition probability from state i to j ) and that state 0 is
reachable from every other state. Note that a stationary DTMC would not be appropriate for modeling
long periods, as age-based mortality would become a significant factor. However, it is reasonable for
shorter periods for which the patient would not survive without a medical intervention. As discussed
earlier, for a DTMC, the choice of the length of the time step is important. We assume data are available
and transitions are Markovian at the chosen time step. The time steps of a Markov model of disease
progression may be thought of as the frequency with which patients’ health state is measured and/or a
treatment decision is considered. For example, if a patient is to have monthly check-ups, the TPM would
reflect monthly transition probabilities, which we assume for the remainder of the paper. We further
assume a distribution  of starting states, that is, i represents the proportion of initial observations in
living state i , with 0 D 0.
3.2. Reduced-model transition probability matrices
The original observable health states are partitioned into a reduced-state model containing K 6 J
states (K D J implies there is no lumping and the complete-state model is retained). Let orig-
inal state i 2 f1; : : : ; J g be assigned to reduced-model state s.i/ 2 f1; : : : ; Kg and also define
S.k/ D fi W s.i/ D kg. We assume lumping is carried out in such a way that state 0 (patient death)
remains its own state, s.0/ D 0, and s.1/ D 1, and either s.i C 1/ D s.i/ or s.i C 1/ D 1 C s.i/ for
1 6 i 6 J , that is, each S.k/ is a contiguous subset of the original observable states.












The pij ’s are weighted by i ’s, which are proportional to the long-run state-by-state observation prob-
abilities. To obtain  , we consider a related, ergodic Markov chain in which the death state is transient,
such that every time a patient dies, a new patient enters the system in the following step, according to .
In other words, we replace the first row of P with the  vector, augmented with p00 D 0. We then solve
for the steady-state probabilities,  , of the resulting augmented DTMC, which is ergodic, as all states
reach i D 0 and i > 0.
3.3. Estimating the reduced model from data
We suppose that a modeler has available dataset of M patient trajectories, where a trajectory is defined to
be a sequence of monthly patient state observations from an initial living state until death. Each patient’s
initial state is generated according to the distribution , and transitions are sampled according to P until
death. We let nij represent the number of observed transitions from state i to state j across the M patient




We let OQ represent the empirical TPM for the reduced-state model based on the M patient trajectories.
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In Appendix A, we show that
lim
N!1 EŒ Oqkl  D qkl ; (3)
where N is the total number of observed transitions, so M ! 1 ) N ! 1.
3.4. Measuring lumping and sampling errors
We measure error in single-step predictions and in predictions of remaining lifetime. When a reduced
model is used, the value Oqkl is treated as the probability that a patient in any original state i 2 S.k/ will
transition in a single step to any state j 2 S.l/. Therefore, for a patient in original state i , the single-
step error created by lumping may be thought of as the difference between qs.i/l and the patient’s true
probability of transitioning, in a single step, to any state j 2 S.l/. The error in the transition probability
estimate, for a patient in state i , is therefore Oqs.i/l  pil , where pil D
X
j2S.l/
pij . An alternative way to
think about error in the transition probabilities is to add the differences between Oqs.i/s.j / and pij for all
j , thus counting the loss of information about differences about the distribution over ‘to’ states as well
as ‘from’ states. However, our measure captures differences in future disease progression across initial
states in s.i/ with the error terms for pil and in errors in remaining lifetime.
We use the limiting value of EŒ Oqkl  (3) in our definitions of lumping and sampling error (below),
which raises the question of how far EŒ Oqkl  is from its limiting value for finite M . We explore this ques-
tion using the simulated data generated as described in Section 3.3, and the results of hypothesis tests
are reported in Appendix A. In hypothesis tests comparing the proportion of observed transitions among
reduced-model states with the probabilities qkl , we find rejection rates of the null hypothesis close to
those predicted by chance, with no trend as a function of M . We conclude that the nonlimiting behavior
with finite M is not different enough to undermine the use of Q in defining metrics of lumping and
sampling error.
By using (3), the expected value of the squared error in the transition probability estimate for a patient
in state i may be broken down as follows:
total error‚ …„ ƒ
E
h Oqs.i/k  pik2iD E h Oqs.i/k  qs.i/kC .qs.i/k  pik/2i (4)
D E
h Oqs.i/k  qs.i/k2iC E hqs.i/k  pik2i (5)
C E 2  Oqs.i/k  qs.i/k .qs.i/k  pik/
D E
h Oqs.i/k  qs.i/k2i„ ƒ‚ …
sampling error
C .qs.i/k  pik/2„ ƒ‚ …
lumping error
(6)
The equality of the expressions in (5) and (6) relies on (3) and the fact that qs.i/k  pik is a con-
stant, so the final term in (5) is zero, leaving (6). As indicated in (6), our metric for lumping error is
.qs.i/k  pik/2, which is inversely related to accuracy of the qkl ’s.
In the limit EŒ. Oqkl  qkl/2 D Var. Oqkl/. As indicated in (6), this term measures sampling error
and decreases with the precision of each estimate Oqkl . We use simulation to estimate Var. Oqkl/, using
R D 100 replications, where each replication r is an independent generation of M patient trajectories
and produces an estimate of the K  K C 1 matrix OQr . For each .k; l/ pair, we calculate the sample
variance, Var. Oqkl/, over the R trials.
We also evaluate errors in the prediction of remaining lifetime implied by the reduced models. The
vector v is the expected lifetime over all initial states, obtained by solving the system of equations
v D 1 C Pv, and the vector u solves u D 1 C Qu, which means u.s.i// is the expected lifetime for a
patient starting in state i , as calculated using the reduced model. To preserve readily interpretable units
of time steps (months), we use ju.s.i//v.i/j rather than its square as a measure of the lumping error in
estimating a patient’s remaining lifetime using the reduced-state TPM Q. Sampling error is estimated as
the average j Our.s.i//  u.s.i//j, where Our.s.i// is the expected survival from aggregate state s.i/ based
on the data-estimated TPM OQr , that is, Our solves Our D 1 C OQr Our .
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Table I. Structure of transition matrix, 0 6 p; ;  < 1,  6 .
State 0 1 2 ... i ... J
0 1 0 0 ... 0 ... 0
1 †1nD1pn p p ... pi1 ... †1nDJ1pn
2 †1nD2pn p p ... pi2 ... †1nDJ2pn
... ... ... ... ... ... ... ...
i †1nDipn p i1 p i2 ... p ... †1nDJipn
... ... ... ... ... ... ... ...
J-1 †1
nDJ1pn pJ2 pJ3 ... pJ1i ... †1nD1pn
J †1
nDJ pn pJ1 pJ2 ... pJi ... †1nD0pn
In considering prediction of remaining lifetime, there is another source of error: the variability inherent
in the Markov chain. Let T .i/ denote the remaining lifetime of a patient currently in state i . If the true
TPM, P , that describes the progression of patient’s disease is known, it yields a probability distribu-
tion over his or her future lifetimes, that is, P.T .i/ D / D p./i0  p.1/i0 . Therefore, Var.T .i// D
EŒ.T .i/  v.i//2 > 0. We will compare lumping and sampling error with EŒj.T .i//  v.i/j, the
expected error due to the stochasticity in the disease process.
3.5. Constructing the experimental transition probability matrices
Although there are no universal features of a disease-progression model, except that death is an absorbing
state, we selected experimental TPMs that have simple structure while capturing reasonable behavior of
disease progression. In particular, the TPMs are constructed to have the decreasing failure rate property,
meaning that patients in better health states have a lower probability of moving to any particular health
state or worse (including death). This property has been observed, for example, in Markov models of
HIV progression [4, 5] and is formalized later. In addition, we assume that the most likely event is that
the patient’s next health state will be identical to his current health state, that is, pi i > pij 8j ¤ i .
We let the transition probabilities pij decrease geometrically as j is further from i , as shown in
Table I. Specifically, we assume that for transitions from states other than i D 0 or i D J , there is a
probability p of remaining in the same state, pm of declining by m states, and pm of improving by
m states in a single time step. The boundary transitions aggregate the sum of probabilities that would
appear if these scalings were to continue in that direction indefinitely. Using the j D 0 and j D J states
to enforce the requirement that the TPM’s rows all sum to one leads to nonmonotonicity at pi0 and piJ .
For pi0, this causes pi0 to decrease in i , implying that patients in poor health states are more likely to
die in a single time step, which is realistic.
Each design is described by a triplet .p; ; /, with  D 1p
1p , which ensures that the rows sum to
one. Because we are modeling disease progression prior to treatment initiation, we let  >  to represent
greater likelihood of worsening health states, while still allowing for improving transitions. High values
of p indicate small single-step changes in health state, whereas (for a given p) low ratios of 

indicate
quickly declining health. Design 1 uses p D 0:1 and  D 0:85, whereas design 2 uses p D 0:3 and
 D 0:65. Therefore, in the disease modeled by design 1, patients’ health state is more variable over
a single time step (expected number of months in each state is approximately 1.1 vs. 1.4 for design 2).
However, health deteriorates more steadily for patients with the disease modeled by design 2; they have a




 0:5 vs. 

 0:9 for design 1

. As detailed in Section 4.2,
expected remaining lifetimes for patients with the design 1 disease range from 2.9 months (for patients
currently in the worst health state) to 42.6 months (for patients in the best health state), whereas they
range from 2.1 to 73.4 months for patients with the design 2 disease.
Transition probability matrices constructed as described earlier have the DFR property. When the
initial health states are naturally ordered, as they are in our model, the DFR property may be defined
as follows:
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2013, 32 3862–3880
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Definition 1




nonincreasing in i for all n 2 f0; : : : ; J g.
Proposition 1
The TPMs described in Table I have the DFR property.
Proof
















































pij is strictly decreasing in i . 
3.6. Measurement error
An important consideration in modeling disease progression based on observational data is measure-
ment error. In the current context, where the underlying model is that the true health state is observable,
measurement error would be reflected in an imperfect observation of the health state. We will model
measurement error as random and independent, that is, observed state Oi is distributed about the true state
i , conditional only on i , but independent of the prior patient’s history or of any other measurement errors.
The system becomes a hidden Markov model, where the unobserved states are the original ‘true’ states
of the model and the observations are the measured states, which have the same indexing, but may be
in error.
Let w
i Oj denote the measurement error probabilities (‘emission probabilities’ in hidden Markov model
terminology); that is, w
i Oj D the probability that the observed state will be Oj given that the true state is
i . A transition from i to j will be observed as a transition from Oi to Oj with probability w
i Oi  wj Oj . The
transitions among measured states will occur according to a TPM OP as given later, with st (Ost ) denoting
a patient’s true (measured) health state in period t .
OpOi Oj D P






























ipij  wi Oiwj Oj
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In general, with measurement error, that is, w
i Oi < 1, the estimated transition probabilities for a given
i will be spread out relative to the underlying TPM, and the standard deviation in OstC1 given Ost D i
calculated using Opij will be larger than the standard deviation in stC1 given st D i calculated using pij .





; i  1 6 Oi 6 i C 1
0 otherwise
.

















The matrix OP is a smoothing of the TPM P ; that is, each Opij is a weighted average of nearby values
of pij . To illustrate further, if we also use our experimental matrix, with pi;iC1 D p, pi;i1 D p ,
and we consider i such that 1 < Oi < J  1 (because of construction of pi0 and piJ terms), and further
assume all j are equal (at least for j D i  1; i; i C 1), then
OpOi Oi D






. C 1/2 C . C 1/2 C 1 (10)
Remembering that 0 6  <  < 1, it is clear that . C 1/2 < . C 1/2 < 4, so OpOi Oi < 59p < p D pi i .
In other words, the highest transition probability from state Oi , OpOi Oi , is smaller than the highest transition
probability from state i , pi i .
Measurement error tends to reduce the probability of observing a transition to the same state
and increase the standard deviation in the next-period measured state for each Oi . Combined with an
underlying TPM similar to design 1, the measurement error would tend to create a behavior more similar
to that associated with design 2. We compare the behavior of the two designs in Section 4.
4. Results and discussion
We explore how the design choice, K, the size of the reduced model, affects errors in estimates of the
TPM and predictions of patient lifetime. We distinguish between lumping errors, which are reflected in
the behavior of the system modeled with reduced TPM Q, and sampling error, which are reflected in the
difference between the behavior of Q and OQ for the same reduction, using R D 100 simulation repli-
cations. Our computational experiments are based on the two TPMs described in Section 3.5. Each has
J D 100 ordered living states and one absorbing (death) state. Throughout, we assume a uniform distri-
bution over initial states, that is, i D 1J 8i D 1; : : : ; J . The reduced model for a given K is determined
by combining contiguous observable health states so that each reduced-model state is assigned the same
number of original states. For values of K that are not integer divisors of J , all reduced-model states
contain either  or C1 original states. We simply assign the reduced-model states containing C1 orig-
inal states to include higher-valued (healthier) states; for example, for J D 10 and K D 4, the reduction
would be s.1/ D s.2/ D 1, s.3/ D s.4/ D 2, s.5/ D s.6/ D s.7/ D 3, and s.8/ D s.9/ D s.10/ D 4.
4.1. Transition probability errors
Figure 1 shows the weighted average squared error in Q and OQ, as a function of reduced-model size,
K and for various M . The error term for each i and k is the left-hand side of Equation (4). The errors
are summarized as a weighted sum of the squared errors in pik over i D 1; : : : ; J and k D 0; 1; : : : ; K,
where the weight  0ipik is the expected relative frequency of transitions from state i to any original state
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2013, 32 3862–3880
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r M = 10, N = 239
M = 20, N = 471
M = 50, N = 1196
M = 100, N = 2396
(a) Design 1




























r M = 10, N = 379
M = 20, N = 756
M = 50, N = 1898
M = 100, N = 3753
(b) Design 2
Figure 1. Weighted average squared errors in TPM as a function of reduced-model size, K. The solid blue line
shows weighted lumping error (11a), and the remaining lines show weighted total error (11b), for various levels
of M . The average number of observed transitions per trial (N ) is also shown.
j 2 S.k/, given Q and . Equation (11a) gives the formula for errors in Q (lumping error), and (11b)










where  0i D
i















Except at very small K, lumping errors in the TPM decline quickly and monotonically in K, as smaller
sets of observable states are lumped together. Lumping error is smaller and falls off more quickly for
design 1 because its single-period transition distribution is broader, so contiguous pij ’s that are lumped
together are less different from each other.
For very small K, average lumping (and total) error is small, because there is a small number of tran-
sition probabilities, hence a small number of opportunities to err in breaking up the total probability over
the ‘to’ states. At the extreme, for K D 1, qs.i/k D 1  qs.i/0 and pik D 1  pi0, implying no error due
to lumping together living ‘to’ states; Equation (11a) will capture only differences in pi0 across i . This
effect is more pronounced for design 2 because its single-period transition probability distributions are
tighter, so there are more large qkl ’s and more qkl ’s that are nearly zero. Thus, for design 1 (Figure 1(a)),
lumping error is maximized for K D 3, and for design 2 (Figure 1(b)), lumping error is maximized for
K D 9. Because very small K will lead to greater errors for longer-horizon predictions, this effect is one
indication that minimizing error in estimating transition probabilities should not be the only objective in
designing a disease-progression model.
The effect of K on total TPM error for the data-derived reduced models is mixed and perhaps coun-
terintuitive. One might expect the sampling error to increase dramatically with very large model size,
because there will be many parameters to estimate from the available observations. Instead, we see sam-
pling error (the difference between the blue line and the green and pink lines in Figure 1) increase slowly
with large K and even decrease in some cases for K very close to 100.
One might also expect the tradeoff between lumping error and sampling error to be much more pro-
nounced. Both lumping error and sampling error substantially affect total error. However, total error
peaks at a low value of K because of lumping error, then drops off dramatically and increases slowly
in K because of the effect of sampling error. If sampling error were the dominant driver of error in
estimating the TPM, we would expect total error to increase in K and reach its maximum for K D 100.
Instead, we see sampling error increase slowly with large K and even decrease in some cases for K
very close to 100. On balance, total error is minimized at larger K, in some cases K D 100 as shown in
Table II (excluding small K < 10).
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Table II. The values of K > 10 that minimize
weighted average error in the TPM, as defined in
(11b); these are the values of K that minimize the
curves shown in Figure 1, after the small-K hump,










In addition, there are interesting differences between the lower-variability TPM (design 1) and the
higher-variability TPM (design 2). Higher variability in measured health state may be created by unpre-
dictable disease progression due to unobserved variables and/or error in measuring the health state. Not
surprisingly, both lumping and sampling errors are larger for the higher-variability TPM (design 2), and
sampling error grows faster, blowing up for very high K when there is a small number of patient trajecto-
ries M D 10 (Figure 1(b)). However, one might expect that high variability would make sampling error
more important and therefore indicate that smaller models are a better choice. Our experiments indicate
that using a small number of states does not mitigate the total error for the high-variability TPM. The
value of K that minimizes total error is larger for design 2 than design 1, at all values of M ; this may be
partly because there are more observations per patient trajectory for design 2.
In general, a modeler is constrained to a given number of patients, M , but may choose the degree of
reduction, K. If the modeler’s objective were to minimize the average value of expected squared TPM
error (4), then he or she might wish to use a model of size K as determined by the available data M ,
shown for our experimental designs in Table II. However, this error-minimizing K is affected by the
structure of the underlying TPM and is higher for design 2 than design 1, for all values of M . Therefore,
a modeler may need to consider the shape of the TPM, as informed by the data or other information on
the course of the disease, as well as the amount of data available.
For very small M D 1; 5, weighted average errors in estimating the TPM are minimized for K D 100.
This may seem counterintuitive especially as the errors are weighted by the frequency with which tran-
sitions are expected to be observed, so errors in small qkl receive less weight. It is because with small
M , very few transitions are observed, and a single observation can produce an estimated Oqkl D 1, hence
a very high error if qkl is small. For small K, these errors have high weights. This effect is another
indication that minimizing error in estimating the TPM is not an objective that captures all relevant
considerations in the choice of K.
Clearly, TPM error is not the only objective of interest to a modeler. According to Figure 1, error
in estimating transition probabilities is minimized for a model with a single living health state; only
one transition probability—the per-step death probability—needs to be estimated. However, this would
not produce a model that has good predictive performance, or, of course, good decision support. In
Section 4.2, we will explore the quality of reduced models’ predictions.
4.2. Remaining lifetime errors
The quality of the estimate of the TPM directly relates to the quality of single-step predictions. However,
we are also interested in longer-horizon predictions that will be affected by both sampling error and loss
of Markovian property due to lumping. For the experimental TPMs considered here, the DFR property
holds strictly (Section 3.5). Therefore, as discussed in Section 2, any null hypothesis of a Markov
chain over reduced-model states is false, on the basis of the construction of TPMs. We examine predic-
tions of remaining lifetime made using reduced models Q and OQ as measure of the models’ predictive
performance over longer horizons.
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(a) Design 1, K = 5




























(b) Design 2, K = 5


























(c) Design 1, K = 10


























(d) Design 1, K = 20
Figure 2. Expected remaining lifetime as a function of initial state, i . The black line shows v.i/, the blue line
shows u.s.i//, and the pink and green lines bound the 90% confidence interval for Ou.s.i// estimated from
M D 10; 20; 50, and 100 simulated patient trajectories as shown (using R D 100 replications).
Figure 2 shows the expected lifetime as a function of starting state i , for the complete model (v.i/), the
reduced model (u.s.i//), and the reduced model estimated from patient data
 NOu.s.i// ˙ 1:645	 Our .s.i//
for various M and K as shown. Expected remaining lifetime (v.i/ shown in black) increases nearly
linearly in i . Because of lumping, u.s.i// and u.s.j // will be identical if s.i/ D s.j /, which produces
the stair steps in expected lifetime for the reduced models (shown in blue).
The most interesting feature in Figure 2 is that the reduced models’ predicted lifetimes systematically
overestimate remaining lifetime for patients in poor health states (small k) and underestimate remaining
lifetime for patients in better health states (larger k). The restriction that the expected lifetime is the same
for all patients in the same lumped state would be expected to create the bias that is observed for patients
in mid-range health states (in Figure 2(a) and (b), see k D 3, that lumps 40 < i 6 60). For the patients in
the middle health states, modeling the expected lifetimes of all patients in each lumped state as identical
tends to over(under)estimate expected lifetimes for patients in worse (better) health—relative to others
in that same lumped state. Note however that for patients in the best health, u.s.i// is an underestimate
for all i 2 S.K/ (the best lumped health state), even for patients who are sicker than the others. This
bias is observed for the best lumped health state in Figure 2(a)–(d), that is, even for K D 20. On the
other end of the health spectrum, expected lifetimes for sick patients are systematically overestimated
for nearly all patients in S.1/, although for the most healthy in each lumped state, u.i/ is approximately
correct. The bias is similar for the two designs (whose construction is described in Section 3.5) and for
other TPMs with an alternative DFR structure.
Figure 3 shows the components of expected error in remaining lifetime, as a function of starting state
i . We can see that for each design, the error due to the stochastic disease progression process, that is, the
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(a) Design 1, K = 5 (b) Design 2, K = 5
(c) Design 1, K = 10 (d) Design 1, K = 20
initial state, i initial state, i
initial state, i initial state, i
Figure 3. Components of absolute error in predicted lifetime, as a function i , for K D 5; 10 and 20 as shown.
The black line shows the contribution from stochasticity in the complete model (12a), the blue line shows the
lumping contribution (12b), and the remaining lines show the sampling error contribution (12c) for various M as
indicated and R D 100.
expected error in a prediction of remaining lifetime even given the complete, correct model P (Equa-
tion 12a), is larger than the contributions due to either lumping (12b) or sampling (12c), even for small
K and small M . Figure 3(c) and (d) shows the components of expected error, for design 1, for K D 10
and K D 20.
EŒjT .i/  v.i/j (12a)





j Our.s.i//  u.s.i//j (12c)
Because of the stair step expected lifetime, the error in u.s.i// (in blue) is cyclical and greater for high
and low i , because of the bias discussed earlier. Sampling error increases monotonically in i , although
it decreases as a proportion of the variability in T .i/.
The variability in T .i/ generally exceeds both sampling and lumping errors in the estimated expected
lifetime, for all values of K, with exceptions only for very low i (poor health states). In other words,
the stochasticity inherent in the disease-progression process is greater than error introduced by either
lumping or sampling error. Of course, lumping and sampling errors further increase the total error in
remaining lifetime predictions, so it is worth exploring the best way to minimize them.
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Figure 4 shows the -weighted sum of expected absolute error in predicted lifetime as a function of
K, as defined in (13), with error due to stochasticity as in (13a), stochasticity plus lumping error as in
(13b), and total stochasticity plus lumping plus sampling error as in (13c). Consistent with the leveling
off of sampling error in the TPM estimate, we observe that the effect of sampling error on remaining
lifetime predictions levels off quickly with K.X
i
 0iEŒjv.i/  T .i/j (13a)
X
i







 0iE Œj Our.s.i//  T .i/j (13c)
Table III shows the value of K that minimizes total expected error in remaining lifetime, as in (13c)
and shown in Figure 4. The most appropriate objective in designing a disease-progression model depends
on its purpose; however, objectives relating to the model’s ability to support good treatment decisions
and produce good patient outcomes are very difficult to measure and depend on models of treated and
untreated disease and preferences over health states. The closest we can have using only the disease-
progression model itself is longer-period predictions. In that sense, the values in Table III may be
considered ‘optimal’.


































































(a) Design 1 (b) Design 2
Figure 4. The -weighted expected absolute error in remaining lifetime for the complete model (black), the
reduced model (blue), and the reduced model estimated from M simulated patient trajectories, as indicated in the
legend. Formulas are given in Equations (13a)–(13c), respectively.
Table III. The values of K that minimize average
absolute expected error in remaining lifetime (curves
in Figure 4, Equation (13c), as a function of M , with











Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2013, 32 3862–3880
E. D. REGNIER AND S. M. SHECHTER
Recall that design 1 had less sampling error in the TPM than design 2 (compare the scales of the
vertical axes in Figure 1), whereas effect of sampling error on predictions of remaining lifetime is larger
for design 1 than for design 2 (Figure 4). This shows that TPM error is not necessarily a good predictor
of error in predictions of remaining lifetime. The focus on the accessible objective of TPM estimation
that may drive modelers’ choice of model reduction is misplaced.
Perhaps surprisingly, lumping error was bigger compared with sampling error and error due to stochas-
ticity of the high-variability TPM (design 2) but not for the lower-variability TPM (design 2). In
Figure 3(b), we see that lumping error exceeds sampling error and error due to stochasticity for most
i for all values of M . In Figure 4, we see that for small M D 10, the contribution of sampling error (the
difference between the pink line and the blue and black lines) is smaller for design 2 (Figure 4(a)) than
design 1 (Figure 4(a)).
Clearly, the optimal model size is dependent on both the amount of data available and the specific
TPM that is being modeled. Most important, the values of K are much larger than the handful that are
typical of disease-progression models in the MDM literature. In addition, the values of K that minimize
expected lifetime error (Table III) are not identical to those that minimize TPM error (Table II). Rather, if
the objective is to minimize error in multi-step predictions, the ‘optimal’ state-space sizes are larger. For
10 patient trajectories, uniformly distributed over 100 starting states, it is expected that 90% of states will
have no patient starting in that state. Many .i; j / pairs will have no observed transitions; the expected
number of nonobserved transitions depends on the TPM. Nevertheless, even for 10 patient trajectories,
the smaller K (design 1) calls for 23 reduced-model states.
5. Application to HIV dataset
Because different diseases have different characteristics, including different numbers of observable
health states, variability of near-term health states for a given current health state, and different rates of
deterioration, the best model size is not a function only of the number of observations. We recommend
that when fitting a Markov chain to observational data, modelers fit the most complete model possible
and then estimate lumping and sampling errors, making the tradeoff as a function of the available data.
We demonstrate this approach on the basis of a dataset of HIV patients, which was used in the MDP
model described in [4]. The primary measure of HIV progression is a patient’s CD4 white blood cell
count, with lower values indicating worse states of health. CD4 counts below 200 are often associated
with acquired immune deficiency syndrome, the end stage of disease caused by HIV. We construct TPMs
on the basis of the CD4 trajectories of 826 HIV patients between the ages of 40 and 50 years and use
cubic splines as discussed in [4] to estimate monthly CD4 counts from HIV diagnosis until death. This
yields a total of 25,737 observed transitions from 1 month until the next across all patients.
First, we perform a similar analysis of the lumping and sampling errors for the TPMs themselves, as
was carried out in Figure 1 for the hypothetical disease-progression models. We take as the baseline TPM
that which arises when we group CD4 by 5’s (this provides better stability when calculating expected
lifetimes compared with grouping by 1’s). Our dataset contains CD4 counts over the range [0,1888];
therefore, the complete model has J D 1888
5
D 378 states. We use the empirical TPM obtained from the
entire set of 25,737 transitions to approximate the expected TPM under various bin sizes to obtain the
Oqkls, according to Equation (2). Figure 5 shows the average lumping error as a function of model size
(K). Note that the general pattern for the actual data has similar features to the hypothetical examples.
For example, in Figure 1(b), the lumping error peaks at K  J
10
.K D 9; J D 100/. For the HIV data,
the peak is also at a value of K  J
10
.K D 38; J D 378/.
Also recall from Figure 1 that the sampling error was relatively insensitive to increasing model size
(less aggregation). Figure 6 tells a similar story for the HIV data; the average sampling error is fairly
stable across the model sizes, for varying numbers of observations (we use number of observed transi-
tions as the measure here). For larger numbers of observed transitions, sampling error even declines with
larger K.
Next, we consider the bias and sampling errors surrounding the calculations of expected remaining
lifetimes, according to model size and quantity of data available. Figure 7, based on the HIV data, is
analogous to Figure 2, based on the hypothetical TPMs. Notably, a systematic bias in expected life-
time observed in the experimental context also occurs in the models created from the real dataset.
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Figure 5. Lumping error, calculated using Equation (11a), as a function of reduced-model size, K. Recall that
J D 378.
Figure 6. Average variance in TPM estimates as a function of the reduced model size and quantity of data
available. The average variance is estimated as Equations (11b).
Figure 7. Expected remaining lifetime predicted using data-derived transition probability matrices for different
model sizes (K), based on the HIV data.
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Table IV. Average lumping error (Equation (12b)) and sampling error (Equation (12c)) for different model
sizes (K), over R D 100 replications.
Lumping error Sampling error (1000 transitions) Sampling error (2500 transitions)
Model size (months) (months) (months)
K D 9 (bin size D 200) 11.63 8.81 4.30
K D 19 (bin size D 100) 5.47 9.60 4.65
K D 38 (bin size D 50) 2.26 11.12 5.01
Specifically, expected remaining lifetimes predicted by the reduced state-space models overestimate the
expected remaining lifetime for people in poor health states (smaller CD4 counts) and underestimate the
expected remaining lifetime for people in better health states (higher CD4 counts).
The effect of bias on treatment decisions would depend on the rewards associated with the health
states and the progress of the disease once treatment is initiated, so it is impossible to draw general
conclusions about the effect of the bias on treatment decisions. However, if remaining lifetime while
untreated is a major driver of the treatment decision (relative to quality of life as a function of health
state and treatment status, and remaining lifetime once treated), then this bias would tend to bias results
toward earlier treatment (overtreatment).
Table IV compares the effect of model size K on sampling error and shows that whereas lumping error
declines rapidly with K, sampling error rises much more slowly. The benefit of reducing model size to
improve parameter estimates appears to be much less important than many modelers assume. When
choosing to reduce the state space, modelers should carefully consider the lumping error created. For
this HIV dataset, the analysis indicates that a model size of K > 200 might produce the best predictions
and treatment recommendations.
6. Conclusions
Our results suggest that lumping error is more important than many modelers realize. A state space of
five living states is typical of disease-progression models in the MDM literature. In our disease models,
with just five states, lumping error can exceed sampling error even for as few as 10 patient trajectories
(Figure 3; averaged over initial state i in Figure 4). The effect is more pronounced for the higher-
variability TPM. The implication is that instead of a predetermined partition of states for a disease
process, the size of the reduced model should depend on the amount of data (number and length of
patient histories) available for estimating the TPM.
As expected, lumping tends to reduce sampling error in estimating the TPM. However, sampling error
increases less than linearly in the size of the reduced-state model and does not increase substantially (and
may even decrease) for large model sizes. More important, error in the TPM is not perfectly related to
error in longer-horizon predictions. For our experimental disease-progression models, error in predicted
lifetimes is minimized by a model with 14 health states, even if there are data for only a single patient.
In general, modelers should consider using larger state spaces, even if the data provide few observa-
tions of each state. Having a relatively imprecise estimate of the TPM may be acceptable if it leads to
a model that is more realistic in its description of the distinctions among health states. If the data are
limited, modelers should consider maintaining a larger model and considering alternatives to observed
relative frequencies for estimating the TPM.
The characteristics of the disease progression, such as the variability in single-step transitions, affect
the tradeoff between lumping and sampling errors. Therefore, the appropriate model size is not a function
only of the number of observations. We recommend that when fitting a Markov chain to observational
data, modelers fit the most complete model possible and then estimate lumping and sampling errors,
making the tradeoff as a function of the available data. We have illustrated using HIV data, which indicate
that the appropriate model size is perhaps 50 times the commonly accepted five states.
Another critically important issue in modeling disease progression with a Markov chain is that lump-
ing creates a systematic bias that leads to overestimating the remaining lifetimes (and distribution of
later health states) for patients in poor health and underestimating the remaining lifetimes for patients
in good health. Effectively, the predicted remaining lifetimes are compressed, relative to the true disease
process, which could have the effect of encouraging similar treatment of patients whose health state
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actually justifies different treatment. This suggests that the violation of the Markovian assumption cre-
ated by lumping undermines the use of a Markov chain model for disease progression. Further work to
develop and evaluate alternative tractable disease-progression models for MDM is warranted.
This paper focuses on the choice of the state-space size for disease-progression models. Because
the details of treatment decisions derived from a disease-progression model also depend on the deci-
sion model (rewards and treatment options), it is not possible to draw any general conclusions about
bias in treatment decisions associated with model size. If rewards and therefore optimal decisions
do depend on the patient’s health state, a model that makes poor predictions of the patient’s future
health state cannot discriminate among patient groups to provide good treatment recommendations that
differ across patient groups. Therefore, building a model that makes good predictions is a necessary
step to making good treatment recommendations. Further research on the impact of the model size on
treatment recommendations in the context of a particular disease or class of decision models would
be valuable.
Appendix A. Limiting behavior of expected transition probability estimates
In Section 3.4, we use the limiting value of E Œ Oqkl  to develop metrics of sampling and lumping error. In
the following, we will prove the value of the limit.
Let N D total number of transitions observed, and as in Section 3.3, ni D
JX
jD1
nij D the total number
of observed transitions from state i and also the total number of observed steps during which a patient
was in state i . We also define nk D
X
i2S.k/















As in Section 3.2, we consider the ergodic Markov chain in which the death state is transient, such that
every time a patient dies, a new patient enters the system in the following step, according to . The vector




as the steady-state probability of a patient being observed in reduced-model state k. The limiting value
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As defined, nij 6 ni 6 nk ) nijnk and
nij
nk
are both bounded by the constant 1, so the bounded
convergence theorem allows us to swap the limit and expectation operators in (A.4) and (A.5).
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Table A.I. Percentage (%) of .k; l/ pairs for which the null hypothesis nkl
nk
D qkl
is rejected at the 5% level using M simulated patient trajectories and repeated over
R D 100 replications; excludes .k; l/ pairs for which the probability of at least one
observed transition is less than 5%.
K
M 1 5 10 20 25 50 100 Average
Design 1 1 0.0 3.4 2.5 4.5 4.0 9.2 6.1 4.2
5 2.6 4.3 3.0 2.7 3.7 6.8 13.4 5.2
10 1.2 5.4 4.0 3.7 3.7 5.4 11.3 5.0
20 1.1 5.1 3.6 3.7 3.6 4.0 8.2 4.2
25 2.3 5.0 4.4 3.6 3.8 4.2 7.0 4.3
50 3.2 5.0 4.1 4.2 3.9 3.6 5.0 4.1
100 1.1 5.1 4.4 3.8 3.7 3.5 4.0 3.6
Design 2 1 0.0 1.0 2.2 2.3 3.0 5.5 7.9 3.1
5 0.0 1.6 2.1 2.8 2.9 3.8 5.4 2.6
10 0.0 1.5 1.8 2.8 3.7 3.8 4.8 2.6
20 0.0 1.8 2.3 3.9 3.9 3.9 4.3 2.9
25 0.0 1.9 2.0 3.3 3.5 3.8 4.1 2.7
50 1.1 2.1 2.1 3.5 3.5 3.8 4.0 2.8






































































































Table A.I below summarizes the results of hypothesis tests comparing the observed proportion nkl
nk
with the corresponding qkl for every .k; l/ pair in the reduced model of size K using R D 100 inde-














would be rejected at the ˛ D 0:05 level. We exclude any case in
which the probability of at least one observed transition is less than 5%;‡ as many of these instances
occur (because, especially for larger K, many of the qkl transition probabilities are very close to zero),
they would bias the results to frequent nonrejections of the null.
‡We exclude .k; l/ pairs for which P.X D 0/> 0:95 when X  Binomial.nk; qkl/.
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These results show no systematic trend as a function of M , indicating that EŒ Oqkl  is very close to qkl
or that any difference is swamped by the bias that may remain from qkl close to zero.
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